DOI QR코드

DOI QR Code

Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology

  • Kattan, Joseph (Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Eid, Roland (Internal Medicine, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Kourie, Hampig Raphael (Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Farhat, Fadi (Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Ghosn, Marwan (Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Ghorra, Claude (Department of Pathology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Tomb, Roland (Department of Dermatology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University)
  • Published : 2016.08.01

Abstract

Background: Mesotheliomas are relatively rare tumors in Lebanon. The only previous study goes back to 14 years ago, when we published epidemiological characteristics of mesotheliomas in Lebanon, showing that the pleural location accounted for the vast majority of cases, with clear evidence of asbestos exposure from the Eternit factory of Chekka region. The objective of this current study was to estimate the incidence of mesothelioma in the past decade and to identify its epidemiological, clinical and therapeutic characteristics, making comparisons with our first study published in 2001. Materials and Methods: Between 2002 and 2014, patients diagnosed with malignant mesothelioma at Hotel-Dieu de France University Hospital were investigated. Epidemiological data focusing on asbestos exposure history were collected from medical records and interviews with the families. Results: A total of 26 patients were diagnosed with mesothelioma, 21 of which were successfully investigated. The mean age of these 21 patients is 62.5 (19-82). Only 3 (14.29%) are women. 18 (85.71%) were smokers. Among the 21 available mesotheliomas, 15 (71.4%) are pleural, while 5 (23.8%) are peritoneal and 1 (4.8%) pericardial. Only 60% of patients with pleural mesothelioma and 50% of those with an obvious exposure to asbestos lived and/or worked in Chekka region. The mean time of asbestos exposure in patients with mesothelioma is 24.5 (1-50) years and the mean latency is 37.4 (4-61) years. Of the 21 patients, 10 (47.6%) underwent surgery during their treatment, 16 (76.2%) received chemotherapy and 3 (14.3%) received best supportive care. Conclusions: Compared to the previous study (1991-2000), substantial changes in the epidemiology of mesothelioma in Lebanon were observed, such as an increase in peritoneal localizations and a lower correlation with Chekka region asbestos contamination.

Keywords

Pleural mesothelioma;peritoneal mesothelioma;Lebanon (capital L);Chekka (capital C);asbestos

References

  1. Antman K, Hassan R, Eisner M, et al (2005). Update on malignant mesothelioma. Oncol, 19, 1301-9.
  2. Bridda A1, Padoan I, Mencarelli R, et al (2007). Peritoneal mesothelioma: a review. Med Gen Med, 9, 32.
  3. Busch JM, Kruskal JB, Wu B, et al (2002). Malignant peritoneal mesothelioma. Radiographics, 22, 1511-15. https://doi.org/10.1148/rg.226025125
  4. Chahinian AP, Pajak TF, Holland JF, et al (1982). Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med, 96, 746-55. https://doi.org/10.7326/0003-4819-96-6-746
  5. Challita S, Guerder A, Charpentier MC, et al (2015). Mesothelioma and familial Mediterranean fever: A relationship? Rev Mal Respir, 32, 271-4. https://doi.org/10.1016/j.rmr.2014.06.029
  6. Cicala C, Pompetti F, Carbone M (1993). SV40 induces mesotheliomas in hamsters. Am J Pathol, 142, 1524-33
  7. Gennaro V, Finkelstein MM, Ceppi M, et al (2000). Mesothelioma and lung tumors attributable to asbestos among petroleum workers. Am J Ind Med, 37, 275-82. https://doi.org/10.1002/(SICI)1097-0274(200003)37:3<275::AID-AJIM5>3.0.CO;2-I
  8. Gibbs AR (1990). Role of asbestos and other fibres in the development of diffuse malignant mesothelioma. Thorax. 45, 649-54. https://doi.org/10.1136/thx.45.9.649
  9. Hershcovici T, Chajek-Shaul T, Hasin T, et al (2006). Familial Mediterranean fever and peritoneal malignant mesothelioma: a possible association? Isr Med Assoc J, 8, 509-11.
  10. Jernelov A (2006). The Environmental Fall-out of the War in Lebanon. Jordan Times.
  11. Kattan J, Faraj H, Ghosn M, et al (2001). Mesotheliome - Asbeste au Liban : Un probleme a retenir. J Med Lib, 49, 333-7
  12. Kazan-Allen L (2015) . Chronology of national asbestos bans.
  13. Le Stang N, Belot A, Gilg Soit Ilg A, et al (2010). Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005. Int J Cancer. 126, 232-8. https://doi.org/10.1002/ijc.24711
  14. Metintas S, Metintas M, Ucgun I, et al (2002). Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest, 122, 2224-29. https://doi.org/10.1378/chest.122.6.2224
  15. Raptopoulos V (1985). Peritoneal mesothelioma. Crit Rev Diagn Imaging, 24, 293-328.
  16. Schutte W, Blankenburg T, Lauerwald K, et al (2003). A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer, 4, 294-7. https://doi.org/10.3816/CLC.2003.n.009
  17. Testa JR, Cheung M, Below JE, et al (2011). Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 43, 1022-5. https://doi.org/10.1038/ng.912
  18. Teta MJ, Mink PJ, Lau E, et al (2008). US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev, 17, 525-34. https://doi.org/10.1097/CEJ.0b013e3282f0c0a2